Telomir Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Telomir Pharmaceuticals, a preclinical-stage biotech, reports progress on its lead compound Telomir-1 and announces a merger with TELI Pharmaceuticals to consolidate global intellectual property rights, despite ongoing net losses and a going concern warning.
NASDAQ
10-K: Telomir Pharmaceuticals Reports Full Year 2024 Results, Highlights Progress of Telomir-1 Development
Telomir Pharmaceuticals details its 2024 financial results and provides an update on the development of its lead drug candidate, Telomir-1, focusing on age-related diseases and metal ion regulation.
NASDAQ
Telomir Pharmaceuticals' 10-K filing details their pre-clinical development of TELOMIR-1, focusing on osteoarthritis, hemochromatosis, and post-chemotherapy recovery.